Structure Based Activity Prediction of HIV-1 Reverse Transcriptase Inhibitors
- 15 January 2005
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 48 (6) , 2176-2183
- https://doi.org/10.1021/jm049534r
Abstract
We have developed a fast and robust computational method for prediction of antiviral activity in automated de novo design of HIV-1 reverse transcriptase inhibitors. This is a structure-based approach that uses a linear relation between activity and interaction energy with discrete orientation sampling and with localized interaction energy terms. The localization allows for the analysis of mutations of the protein target and for the separation of inhibition and a specific binding to the enzyme. We apply the method to the prediction of pIC50 of HIV-1 reverse transcriptase inhibitors. The model predicts the activity of an arbitrary compound with a q2 of 0.681 and an average absolute error of 0.66 log value, and it is fast enough to be used in high-throughput computational applications.Keywords
This publication has 9 references indexed in Scilit:
- SYNOPSIS: SYNthesize and OPtimize System in SilicoJournal of Medicinal Chemistry, 2003
- Prediction of Activity for Nonnucleoside Inhibitors with HIV-1 Reverse Transcriptase Based on Monte Carlo SimulationsJournal of Medicinal Chemistry, 2002
- The Protein Data BankNucleic Acids Research, 2000
- A new method for predicting binding affinity in computer-aided drug designProtein Engineering, Design and Selection, 1994
- Inhibition of HIV-1 Replication by a Nonnucleoside Reverse Transcriptase InhibitorScience, 1990
- Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivativesNature, 1990
- Minimizing multimodal functions of continuous variables with the “simulated annealing” algorithm—Corrigenda for this article is available hereACM Transactions on Mathematical Software, 1987
- The AIDS VirusScientific American, 1987
- 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.Proceedings of the National Academy of Sciences, 1985